New painkiller could cut opioid use after shoulder surgery
NCT ID NCT07410182
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares a long-acting numbing drug (liposomal bupivacaine) to the standard version for pain relief after shoulder surgery. About 60 adults aged 18-60 will receive one of the two drugs as a nerve block before surgery. Researchers will track how much opioid pain medicine they need and their pain levels for 3 days after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liposomal bupivacaine (a long-acting numbing medicine)
- What this could lead to
- If it works, this could provide better pain control and reduce the need for opioids after shoulder surgery.
- What could go wrong
- This is a small, early-phase trial with only 60 people, so results may not apply to everyone. The liposomal version may not work better than the standard drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHROSCOPIC SHOULDER SURGERY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nerve block beat standard pain relief for shoulder surgery?
- Could a lower dose of spinal anesthetic protect elderly patients during surgery?
- Shoulder block study checks for breathing side effects
- Electricity meets ultrasound: a smarter way to target nerves?
- Shoulder surgery nerve block showdown: which one spares your diaphragm?
- New cocktail could keep knee surgery patients Pain-Free longer